{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:09:25Z","timestamp":1790118565031,"version":"4.0.1"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ijpharm.2019.05.033","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T06:38:54Z","timestamp":1558420734000},"page":"410-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption"],"prefix":"10.1016","volume":"566","author":[{"given":"Ahmed A. Abdulhussein","family":"Al-Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1684-215X","authenticated-orcid":false,"given":"Rasmus Blaaholm","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Steffansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Uhd","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2019.05.033_b0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/acs.molpharmaceut.7b00772","article-title":"High expression of UGT1A1\/1A6 in monkey small intestine: comparison of protein expression levels of cytochromes P450, UDP-glucuronosyltransferases, and transporters in small intestine of cynomolgus monkey and human","volume":"15","author":"Akazawa","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jddst.2015.05.003","article-title":"Potential of a novel self nanoemulsifying carrier system to overcome P-glycoprotein mediated efflux of etoposide: In vitro and ex vivo investigations","volume":"28","author":"Akhtar","year":"2015","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13318-016-0332-7","article-title":"The ameliorated pharmacokinetics of VP-16 in wistar rats: a possible role of P-glycoprotein inhibition by pharmaceutical excipients","volume":"42","author":"Akhtar","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijpharm.2018.09.039","article-title":"Nonionic surfactants increase digoxin absorption in Caco-2 and MDCKII MDR1 cells: impact on P-glycoprotein inhibition, barrier function, and repeated cellular exposure","volume":"551","author":"Al-Ali","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijpharm.2018.04.006","article-title":"Polysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-Dawley rats","volume":"543","author":"Al-Ali","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0035","first-page":"4237","article-title":"The mouse Bcrp1\/Mxr\/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin","volume":"59","author":"Allen","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0040","first-page":"1339","article-title":"Mouse breast cancer resistance protein (Bcrp1\/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein","volume":"63","author":"Allen","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0045","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijpharm.2015.12.017","article-title":"Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo","volume":"498","author":"Al-Saraf","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0055","doi-asserted-by":"crossref","first-page":"21160","DOI":"10.1074\/jbc.272.34.21160","article-title":"Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein","volume":"272","author":"Ambudkar","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/np0203537","article-title":"A new P-glycoprotein inhibitor from the caper spurge (Euphorbia lathyris)","volume":"66","author":"Appendino","year":"2003","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijpharm.2011.02.059","article-title":"The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers","volume":"409","author":"Ashiru-Oredope","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/bbrc.1993.2487","article-title":"Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport","volume":"197","author":"Augustijns","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0075","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1023\/A:1018942823676","article-title":"Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells","volume":"16","author":"Batrakova","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0080","first-page":"551","article-title":"Pluronic P85 enhances the delivery of digoxin to the brain. in vitro and in vivo studies","volume":"296","author":"Batrakova","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0085","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/jpet.102.043307","article-title":"Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells","volume":"304","author":"Batrakova","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0090","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1023\/A:1026179132599","article-title":"Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85","volume":"20","author":"Batrakova","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0095","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s11095-004-7675-5","article-title":"Effect of pluronic P85 on ATPase activity of drug efflux transporters","volume":"21","author":"Batrakova","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0100","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.24496","article-title":"Head-to-head comparison of different solubility-enabling formulations of etoposide and their consequent solubility-permeability interplay","volume":"104","author":"Beig","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejpb.2017.09.012","article-title":"Concomitant solubility-permeability increase: vitamin E TPGS vs. amorphous solid dispersion as oral delivery systems for etoposide","volume":"121","author":"Beig","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0110","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/jps.20057","article-title":"Cyclosporin nanoparticulate lipospheres for oral administration","volume":"93","author":"Bekerman","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0115","first-page":"684","article-title":"Improvement of the bioavailability of colchicine in rats by co-administration of D-\u03b1-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid","volume":"52","author":"Bittner","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0120","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/jps.10395","article-title":"The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins","volume":"92","author":"Bogman","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clpt.2004.09.001","article-title":"P-glycoprotein and surfactants: effect on intestinal talinolol absorption","volume":"77","author":"Bogman","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0130","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1476-5381.2012.02030.x","article-title":"Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol","volume":"167","author":"Broberg","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/bdd.2025","article-title":"Caco-2 cells \u2013 expression, regulation and function of drug transporters compared with human jejunal tissue: transporter expression, regulation and function in Caco-2 cells","volume":"38","author":"Br\u00fcck","year":"2017","journal-title":"Biopharm. Drug Disposition"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0140","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ijc.2910620413","article-title":"Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid sulfactants as multidrug resistance modification agents","volume":"62","author":"Buckingham","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0145","series-title":"The ABCs of Drug Transport in Intestine and Liver: Efflux Proteins Limiting Drug Absorption and Bioavailability","first-page":"25","author":"Chan","year":"2004"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0092-8674(86)90595-7","article-title":"Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells","volume":"47","author":"Chen","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0155","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/acs.molpharmaceut.7b00374","article-title":"Pluronic P85\/F68 micelles of baicalein could interfere with mitochondria to overcome MRP2-mediated efflux and offer improved anti-parkinsonian activity","volume":"14","author":"Chen","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0160","first-page":"1463","article-title":"Pluronic mixed micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation","volume":"8","author":"Chen","year":"2013","journal-title":"Int J Nanomed."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade","volume":"370","author":"Chen","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0170","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1023\/A:1023481418576","article-title":"Human jejunal permeability of cyclosporin a: influence of surfactants on P-glycoprotein efflux in Caco-2 cells","volume":"20","author":"Chiu","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0175","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1248\/bpb.b14-00508","article-title":"Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and Tween80 in rats","volume":"38","author":"Choi","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0180","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejps.2010.07.005","article-title":"Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes","volume":"41","author":"Christiansen","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0185","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1039\/C6MD00005C","article-title":"SLC transporters: structure, function, and drug discovery","volume":"7","author":"Colas","year":"2016","journal-title":"MedChemComm"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0190","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/mp060121r","article-title":"Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity","volume":"4","author":"Collnot","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0195","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/mp900191s","article-title":"Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access","volume":"7","author":"Collnot","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0200","first-page":"897","article-title":"Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance","volume":"51","author":"Coon","year":"1991","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ijpharm.2019.05.033_b9000","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/38.9.1974900","article-title":"Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues","volume":"38","author":"Cordon-Cardo","year":"1990","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2004.03.001","article-title":"Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo","volume":"278","author":"Cornaire","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0210","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jps.21246","article-title":"Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs","volume":"97","author":"Cuin\u00e9","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2478\/s11658-008-0041-6","article-title":"Oral cyclosporine A \u2013 the current picture of its liposomal and other delivery systems","volume":"14","author":"Czogalla","year":"2009","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0220","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1002\/jps.22033","article-title":"The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone","volume":"99","author":"Dahan","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0225","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/pr.58.2.3","article-title":"Multidrug resistance-associated proteins: expression and function in the central nervous system","volume":"58","author":"Dallas","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0230","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/1097-0142(19950201)75:3<815::AID-CNCR2820750311>3.0.CO;2-R","article-title":"A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study","volume":"75","author":"Dalton","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0235","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ejps.2013.04.036","article-title":"In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine","volume":"49","author":"Devraj","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0240","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/gut.52.12.1788","article-title":"ABC of oral bioavailability: transporters as gatekeepers in the gut","volume":"52","author":"Dietrich","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0245","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/0008-5472.CAN-08-2747","article-title":"Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP","volume":"69","author":"Dong","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0250","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","article-title":"Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)","volume":"22","author":"Doyle","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0255","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2125.1992.tb04108.x","article-title":"Enhancement of the oral absorption of cyclosporin in man","volume":"34","author":"Drewe","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0260","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/mp500330y","article-title":"Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine","volume":"11","author":"Drozdzik","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0265","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1301","article-title":"Protein abundance of clinically relevant drug transporters in the human liver and intestine: a comparative analysis in paired tissue specimens","author":"Drozdzik","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0270","unstructured":"Drugbank, 2019. P-glycoprotein substrates. https:\/\/www.drugbank.ca\/unearth\/q?utf8=%E2%9C%93&searcher=drugs&query=P-glycoprotein+substrate. (accessed 01.003.2019)."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0275","series-title":"Polyethylene Glycol (PEG): A Versatile Polymer for Pharmaceutical Applications England","first-page":"1257","author":"D'Souza","year":"2016"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0285","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1208\/pt020319","article-title":"In vitro assessment of alkylglycosides as permeability enhancers","volume":"2","author":"Eley","year":"2001","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0290","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1021\/mp3001815","article-title":"Pharmaceutical excipients influence the function of human uptake transporting proteins","volume":"9","author":"Engel","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0295","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ibd.20030","article-title":"Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1)","volume":"13","author":"Englund","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0300","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/bbrc.1995.2617","article-title":"Regional expression and dietary regulation of rat small intestinal peptide and amino acid transporter mRNAs","volume":"216","author":"Erickson","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0305","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1054\/bjoc.2000.1260","article-title":"Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport","volume":"83","author":"Evers","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0310","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/j.biomaterials.2006.08.004","article-title":"In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein","volume":"27","author":"F\u00f6ger","year":"2006","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0315","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1476-5381.1996.tb15612.x","article-title":"Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation","volume":"118","author":"Fricker","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0320","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","article-title":"Importance of P-glycoprotein at blood\u2013tissue barriers","volume":"25","author":"Fromm","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0330","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0009-9236(99)70031-7","article-title":"Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil","volume":"66","author":"Gramatt\u00e9","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0335","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2004.07.048","article-title":"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)","volume":"22","author":"Greenberg","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0340","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpba.2013.07.031","article-title":"LC\u2013MS\/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins","volume":"85","author":"Gr\u00f6er","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0345","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s12272-011-1016-0","article-title":"Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism","volume":"34","author":"Guan","year":"2011","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0350","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00280-005-0173-6","article-title":"Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan","volume":"58","author":"Gupta","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0355","first-page":"1309","article-title":"Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A","volume":"56","author":"Gupta","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0360","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/jpet.104.065342","article-title":"HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"310","author":"Gupta","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0365","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1021\/acs.molpharmaceut.8b00482","article-title":"Inhibitory effects of commonly used excipients on P-glycoprotein in vitro","volume":"15","author":"Gurjar","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0370","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejpb.2010.06.008","article-title":"Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2)","volume":"76","author":"Hanke","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0375","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/bdd.1810","article-title":"Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro\u2013in vivo extrapolation of oral drug absorption","volume":"34","author":"Harwood","year":"2013","journal-title":"Biopharm. Drug Disposition"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0380","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpba.2015.02.043","article-title":"Application of an LC\u2013MS\/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique","volume":"110","author":"Harwood","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0385","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00424-003-1192-y","article-title":"The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins","volume":"447","author":"Hediger","year":"2004","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0390","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mam.2012.12.009","article-title":"The ABCs of membrane transporters in health and disease (SLC series): introduction","volume":"34","author":"Hediger","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0400","first-page":"745","article-title":"Effects of polyethylene glycols on intestinal efflux pump expression and activity in Caco-2 cells","volume":"51","author":"Hodaei","year":"2015","journal-title":"BJPS"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0405","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0410","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/jps.10176","article-title":"A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro","volume":"91","author":"Hugger","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0415","unstructured":"HUGO Gene Nomenclature Committee, 2019. ATP binding cassette transporters (ABC). https:\/\/www.genenames.org\/cgi-bin\/genefamilies\/set\/417. Solute carriers (SLC). https:\/\/www.genenames.org\/cgi-bin\/genefamilies\/set\/752., (accessed 12.01.2019)."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0420","first-page":"4595","article-title":"In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative","volume":"53","author":"Hyafil","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0425","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.drudis.2006.07.015","article-title":"Disease, destination, dose and delivery aspects of ciclosporin: the state of the art","volume":"11","author":"Italia","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0430","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/17425255.2.3.351","article-title":"Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition","volume":"2","author":"Jedlitschky","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0435","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1208\/ps040440","article-title":"An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine","volume":"4","author":"Johnson","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0440","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2017.01.041","article-title":"Structural basis of substrate recognition by the multidrug resistance protein MRP1","volume":"168","author":"Johnson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0445","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/jnci\/92.20.1651","article-title":"Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan","volume":"92","author":"Jonker","year":"2000","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0450","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0455","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ijc.2910500418","article-title":"SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia","volume":"50","author":"Keller","year":"1992","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0460","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1126\/science.aar7389","article-title":"Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation","volume":"359","author":"Kim","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0465","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/jps.24085","article-title":"Sucrose esters increase drug penetration, but do not inhibit P-glycoprotein in Caco-2 intestinal epithelial cells","volume":"103","author":"Kiss","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0470","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","article-title":"Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications","volume":"24","author":"Koepsell","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0475","first-page":"3537","article-title":"Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines","volume":"57","author":"Kool","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0480","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1073\/pnas.96.12.6914","article-title":"MRP3, an organic anion transporter able to transport anti-cancer drugs","volume":"96","author":"Kool","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0485","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1073\/pnas.1324141111","article-title":"Structure of sugar-bound LacY","volume":"111","author":"Kumar","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0490","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1073\/pnas.1801774115","article-title":"Crystal Structure of a ligand-bound LacY\u2013Nanobody Complex","volume":"115","author":"Kumar","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0495","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2006.02.014","article-title":"Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition","volume":"112","author":"Lamprecht","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0500","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/bjc.1998.192","article-title":"Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer","volume":"77","author":"Lehnert","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0505","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.02.016","article-title":"Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS)","volume":"447","author":"Li","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0510","doi-asserted-by":"crossref","first-page":"447","DOI":"10.18433\/J3VP5H","article-title":"Inhibition of human efflux transporter ABCC2 (MRP2) by self-emulsifying drug delivery system: influences of concentration and combination of excipients","volume":"17","author":"Li","year":"2014","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0515","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.bbamem.2009.07.010","article-title":"Detergents as intrinsic P-glycoprotein substrates and inhibitors","volume":"1788","author":"Li-Blatter","year":"2009","journal-title":"BBA -Biomembranes"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0520","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1016\/j.bpj.2010.10.033","article-title":"Exploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers","volume":"99","author":"Li-Blatter","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0525","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.bpj.2012.02.018","article-title":"P-glycoprotein-ATPase modulation: the molecular mechanisms","volume":"102","author":"Li-Blatter","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0530","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1248\/bpb.30.1301","article-title":"Effects of labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats","volume":"30","author":"Lin","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0535","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0540","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/acs.molpharmaceut.5b00656","article-title":"Oral morphine pharmacokinetic in obesity: the role of P-glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 jejunal contents and obesity-associated biomarkers","volume":"13","author":"Lloret-Linares","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0545","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0168-3659(03)00163-9","article-title":"Relationships between the hydrophilic\u2013lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines","volume":"90","author":"Lo","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0550","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","article-title":"Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine","volume":"62","author":"Lown","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0555","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s12272-011-1114-z","article-title":"Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats","volume":"34","author":"Ma","year":"2011","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0560","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0565","first-page":"935","article-title":"Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins in Vitro Using Non-Substrate Drugs or the BCRP Inhibitor GF120918","volume":"7","author":"Maliepaard","year":"2001","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0570","first-page":"3458","article-title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues","volume":"61","author":"Maliepaard","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0575","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1208\/aapsj070112","article-title":"Role of the breast cancer resistance protein (ABCG2) in drug transport","volume":"7","author":"Mao","year":"2005","journal-title":"The AAPS J."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0580","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2014an update","volume":"17","author":"Mao","year":"2015","journal-title":"The AAPS J."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0585","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","article-title":"Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs","volume":"26","author":"Matsson","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0590","first-page":"389","article-title":"Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin","volume":"4","author":"Mechetner","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0595","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/mp200181v","article-title":"The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation","volume":"8","author":"Miller","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0600","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1021\/acs.molpharmaceut.6b00085","article-title":"Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects","volume":"13","author":"Miyauchi","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0605","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1208\/s12249-012-9787-2","article-title":"Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion","volume":"13","author":"Mohsin","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0610","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000026910","article-title":"Alteration in epirubicin pharmacokinetics and metabolism by dexverapamil: results from a phase ii study in patients with metastatic breast cancer","volume":"22","author":"Mross","year":"1999","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0615","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1023\/A:1016033702220","article-title":"The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system","volume":"13","author":"Nerurkar","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0620","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijpharm.2016.09.011","article-title":"Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-\/-) Sprague Dawley rats","volume":"513","author":"Nielsen","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0625","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","article-title":"The apical conjugate efflux pump ABCC2 (MRP2)","volume":"453","author":"Nies","year":"2007","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0630","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.xphs.2015.10.030","article-title":"The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition","volume":"105","author":"\u00d6lander","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0635","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0006-3495(86)83707-9","article-title":"Effects of cyclosporine A on biomembranes. Vibrational spectroscopic, calorimetric and hemolysis studies","volume":"49","author":"O'Leary","year":"1986","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0640","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clpt.2005.11.004","volume":"79","author":"Oswald","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0645","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejpb.2016.11.028","article-title":"Effects of frequently used pharmaceutical excipients on the organic cation transporters 1\u20133 and peptide transporters 1\/2 stably expressed in MDCKII cells","volume":"112","author":"Otter","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0650","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.phymed.2015.08.006","article-title":"Enhanced oral bioavailability and anticancer activity of novel curcumin loaded mixed micelles in human lung cancer cells","volume":"22","author":"Patil","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0655","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejps.2012.08.010","article-title":"Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers","volume":"47","author":"Petersen","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0660","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00280-004-0854-6","article-title":"A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors","volume":"55","author":"Planting","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0665","first-page":"127","article-title":"Cyclosporine bioavailability of two physically different oral formulations","volume":"6","author":"Postolache","year":"2002","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0670","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","article-title":"Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system","volume":"29","author":"Pouton","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0675","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jmb.2011.02.008","article-title":"The alternating-access mechanism of MFS transporters arises from inverted-topology repeats","volume":"407","author":"Radestock","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0680","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1073\/pnas.96.7.3900","article-title":"Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier","volume":"96","author":"Rao","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0690","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0928-0987(02)00055-6","article-title":"Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers","volume":"16","author":"Rege","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0695","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1432-1327.1999.00037.x","article-title":"Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells","volume":"259","author":"Regev","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0700","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02988570","article-title":"Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I-II clinical trial","volume":"8","author":"Ries","year":"1991","journal-title":"Med. Oncol. Tumor Pharmacother."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0710","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.str.2010.01.017","article-title":"The human breast cancer resistance protein (BCRP\/ABCG2) shows conformational changes with mitoxantrone","volume":"18","author":"Rosenberg","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0715","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1107\/S1399004715010676","article-title":"Three-dimensional structure of the human breast cancer resistance protein (BCRP\/ABCG2) in an inward-facing conformation","volume":"71","author":"Rosenberg","year":"2015","journal-title":"Acta Crystallogr. Sect. D"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0720","first-page":"319","article-title":"Lipid excipients Peceol and Gelucire 44\/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells","volume":"10","author":"Sachs-Barrable","year":"2007","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0725","doi-asserted-by":"crossref","first-page":"11653","DOI":"10.1074\/jbc.M011294200","article-title":"Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes","volume":"276","author":"Sauna","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0730","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/03639045.2017.1342654","article-title":"Review and analysis of FDA approved drugs using lipid-based formulations","volume":"43","author":"Savla","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0735","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2018.07.011","article-title":"Effects of various pharmaceutical excipients on the intestinal transport and absorption of sulfasalazine, a typical substrate of breast cancer resistance protein transporter","volume":"107","author":"Sawangrat","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2018.07.011","article-title":"Modulation of intestinal transport and absorption of topotecan, a BCRP substrate by various pharmaceutical excipients and their inhibitory mechanisms of BCRP transporter","author":"Sawangrat","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0745","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1432-1327.1998.2510252.x","article-title":"A general pattern for substrate recognition by P-glycoprotein","volume":"251","author":"Seelig","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0750","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/17425255.2.5.733","article-title":"Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding","volume":"2","author":"Seelig","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0755","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1002\/jps.21372","article-title":"Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors","volume":"97","author":"Shaik","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0760","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2006.01.020","article-title":"Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies","volume":"313","author":"Shen","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0765","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1211\/jpp.60.12.0009","article-title":"Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies","volume":"60","author":"Shen","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0770","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1248\/bpb.b15-00445","article-title":"Influence of food on rifampicin pharmacokinetics in rats","volume":"39","author":"Shimomura","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0775","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/jps.20017","article-title":"Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes","volume":"93","author":"Shono","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0780","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2017.01.042","article-title":"Interaction of pharmaceutical excipients with organic cation transporters","volume":"520","author":"Soodvilai","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0785","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00001813-199909000-00005","article-title":"Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein","volume":"10","author":"Sparreboom","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0790","series-title":"Intestinal Solute Carriers: An Overview of Trends and Strategies for Improving Oral Drug Absorption","first-page":"3","author":"Steffansen","year":"2004"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0795","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.xphs.2017.04.033","article-title":"SGLT1-mediated transport in Caco-2 cells is highly dependent on cell bank origin","volume":"106","author":"Steffansen","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0800","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.biocel.2009.08.015","article-title":"Drug transporter, P-glycoprotein (MDR1), is an integrated component of the mammalian blood\u2013testis barrier","volume":"41","author":"Su","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0805","first-page":"1967","article-title":"Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil","volume":"41","author":"Tsuruo","year":"1981","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0810","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.dmpk.2014.11.002","article-title":"Quantitative targeted absolute proteomics for 28 human transporters in plasma membrane of Caco-2 cell monolayer cultured for 2, 3, and 4 weeks","volume":"30","author":"Uchida","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0820","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/bjc.1997.530","article-title":"Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833","volume":"76","author":"vanAsperen","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0825","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejps.2005.04.003","article-title":"Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo","volume":"25","author":"Varma","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0830","doi-asserted-by":"crossref","first-page":"13778","DOI":"10.1021\/bi801644v","article-title":"Membrane topology of the human breast cancer resistance protein (BCRP\/ABCG2) determined by epitope insertion and immunofluorescence","volume":"47","author":"Wang","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0835","first-page":"1451","article-title":"Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen","volume":"4","author":"Warner","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0840","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1021\/acs.molpharmaceut.7b00364","article-title":"Variability in Mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes","volume":"14","author":"Wegler","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0845","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejpb.2010.04.017","article-title":"Enhanced antitumor efficacy by Paclitaxel-loaded Pluronic P123\/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance","volume":"75","author":"Wei","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0850","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejpb.2012.09.014","article-title":"Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123\/F127 block copolymers: relationship between copolymer concentration and inhibitory activity","volume":"83","author":"Wei","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0855","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1124\/dmd.109.027367","article-title":"Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients","volume":"37","author":"Wojtal","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0860","first-page":"4199","article-title":"Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs","volume":"50","author":"Woodcock","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0865","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bjc.1992.217","article-title":"Reversal of multidrug resistance by surfactants","volume":"66","author":"Woodcock","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0870","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejps.2016.08.054","article-title":"A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: activation of MRP3 with concurrent inhibition of MRP2 and BCRP","volume":"93","author":"Xiao","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0875","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1021\/acs.biochem.5b00649","article-title":"Allocrite sensing and binding by the breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)","volume":"54","author":"Xu","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.08.021","article-title":"Effect of excipients on breast cancer resistance protein substrate uptake activity","volume":"124","author":"Yamagata","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0885","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1124\/dmd.106.014217","article-title":"Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients","volume":"35","author":"Yamagata","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0890","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijpharm.2008.12.005","article-title":"Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients","volume":"370","author":"Yamagata","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0895","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.taap.2005.04.001","article-title":"Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli Fructus","volume":"209","author":"Yoshida","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0900","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdd.745","article-title":"Intestinal transport of bis(12)-hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35","volume":"32","author":"Yu","year":"2011","journal-title":"Biopharm. Drug Disposition"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0905","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s13238-015-0148-2","article-title":"The physiological role of drug transporters","volume":"6","author":"Yu Liang Siqi Li Ligong","year":"2015","journal-title":"Protein Cell"},{"key":"10.1016\/j.ijpharm.2019.05.033_b0910","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/BF02976689","article-title":"Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats","volume":"26","author":"Zhang","year":"2003","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0915","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejps.2013.08.016","article-title":"Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition","volume":"50","author":"Zhao","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0920","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.xphs.2016.01.020","article-title":"Effects of polyoxyethylene alkyl ethers on the intestinal transport and absorption of rhodamine 123: A P-glycoprotein substrate by in vitro and in vivo studies","volume":"105","author":"Zhao","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.05.033_b0925","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ejps.2009.05.001","article-title":"Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450","volume":"37","author":"Zhu","year":"2009","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517319303850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517319303850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T21:28:00Z","timestamp":1715203680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517319303850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":180,"alternative-id":["S0378517319303850"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2019.05.033","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2019.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}